skip to content

CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)

Investors

Investor updates
view all

stay updated

get the latest news and updates to your inbox.